1. Home
  2. GYRE vs TMP Comparison

GYRE vs TMP Comparison

Compare GYRE & TMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GYRE
  • TMP
  • Stock Information
  • Founded
  • GYRE 2002
  • TMP 1836
  • Country
  • GYRE United States
  • TMP United States
  • Employees
  • GYRE N/A
  • TMP N/A
  • Industry
  • GYRE Biotechnology: Pharmaceutical Preparations
  • TMP Major Banks
  • Sector
  • GYRE Health Care
  • TMP Finance
  • Exchange
  • GYRE Nasdaq
  • TMP Nasdaq
  • Market Cap
  • GYRE 1.1B
  • TMP 892.4M
  • IPO Year
  • GYRE N/A
  • TMP N/A
  • Fundamental
  • Price
  • GYRE $10.95
  • TMP $66.81
  • Analyst Decision
  • GYRE
  • TMP Buy
  • Analyst Count
  • GYRE 0
  • TMP 2
  • Target Price
  • GYRE N/A
  • TMP $69.00
  • AVG Volume (30 Days)
  • GYRE 129.2K
  • TMP 57.8K
  • Earning Date
  • GYRE 11-13-2024
  • TMP 01-28-2025
  • Dividend Yield
  • GYRE N/A
  • TMP 3.70%
  • EPS Growth
  • GYRE N/A
  • TMP 376.41
  • EPS
  • GYRE N/A
  • TMP 4.64
  • Revenue
  • GYRE $105,033,000.00
  • TMP $286,367,000.00
  • Revenue This Year
  • GYRE $25.32
  • TMP N/A
  • Revenue Next Year
  • GYRE $12.95
  • TMP $7.68
  • P/E Ratio
  • GYRE N/A
  • TMP $14.41
  • Revenue Growth
  • GYRE N/A
  • TMP 30.04
  • 52 Week Low
  • GYRE $8.26
  • TMP $43.09
  • 52 Week High
  • GYRE $26.37
  • TMP $79.01
  • Technical
  • Relative Strength Index (RSI)
  • GYRE 48.93
  • TMP 44.02
  • Support Level
  • GYRE $9.51
  • TMP $62.02
  • Resistance Level
  • GYRE $11.11
  • TMP $69.15
  • Average True Range (ATR)
  • GYRE 0.85
  • TMP 2.14
  • MACD
  • GYRE 0.04
  • TMP 0.11
  • Stochastic Oscillator
  • GYRE 29.33
  • TMP 64.23

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

About TMP Tompkins Financial Corporation

Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.

Share on Social Networks: